Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1375234 | Bioorganic & Medicinal Chemistry Letters | 2008 | 4 Pages |
Lead compound 1 was successfully redesigned to provide compounds with improved pharmacokinetic profiles for this series of human urotensin-II antagonists. Replacement of the 2-pyrrolidinylmethyl-3-phenyl-piperidine core of 1 with a substituted N-methyl-2-(1-pyrrolidinyl)ethanamine core as in compound 7 resulted in compounds with improved oral bioavailability in rats. The relationship between stereochemistry and selectivity for hUT over the κ-opioid receptor was also explored.
Graphical abstractRedesign of the potent human urotensin-II antagonist 1 with the 2-pyrrolidinylmethyl-3-phenyl-piperidine core to a new chemical series with a substituted N-methyl-2-(1-pyrrolidinyl)ethanamine core as in 17 resulted in compounds with improved PK profiles.Figure optionsDownload full-size imageDownload as PowerPoint slide